Literature DB >> 4700011

Amiloride in primary hyperaldosteronism with chronic peptic ulceration.

D Kremer, R Fraser, J J Brown, A F Lever, D L Davies, J I Robertson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4700011      PMCID： PMC1589384          DOI： 10.1136/bmj.2.5860.216

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  11 in total

1.  A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

Authors:  G A ROSE; W W HOLLAND; E A CROWLEY
Journal:  Lancet       Date:  1964-02-08       Impact factor: 79.321

Review 2.  Hypertension and chronic renal failure.

Authors:  J J Brown; G Düsterdieck; R Fraser; A F Lever; J I Robertson; M Tree; R J Weir
Journal:  Br Med Bull       Date:  1971-05       Impact factor: 4.291

3.  Clinical evaluation of amiloride, a potassium-sparing diuretic.

Authors:  A F Lant; A J Smith; G M Wilson
Journal:  Clin Pharmacol Ther       Date:  1969 Jan-Feb       Impact factor: 6.875

4.  Hypertension and hyperaldosteronism with low plasma renin concentration: analysis of a series of eighty-two patients.

Authors:  J J Brown; R H Chinn; G O Düsterdieck; R Fraser; R H Gleadle; A F Lever; J I Robertson; M Tree
Journal:  Proc R Soc Med       Date:  1969-12-12

5.  Use of amiloride in preoperative management of a patient with primary aldosteronism.

Authors:  C H Braren; R G Campbell; S A Hashim; T B Van Itallie
Journal:  Am J Med       Date:  1968-09       Impact factor: 4.965

6.  Amiloride. A potassium-sparing natriuretic agent.

Authors:  M B Bull; J H Laragh
Journal:  Circulation       Date:  1968-01       Impact factor: 29.690

7.  Aldosteronism in hypertension. The spironolactone response test.

Authors:  R F Spark; J C Melby
Journal:  Ann Intern Med       Date:  1968-10       Impact factor: 25.391

8.  Effect of spironolactone in hypertensive patients.

Authors:  M G Crane; J J Harris
Journal:  Am J Med Sci       Date:  1970-12       Impact factor: 2.378

9.  Plasma concentration of renin in a patient with Conn's syndrome with fibrinoid lesions of the renal arterioles: the effect of treatment with spironolactone.

Authors:  J J Brown; D L Davies; A F Lever; W S Peart; J I Robertson
Journal:  J Endocrinol       Date:  1965-10       Impact factor: 4.286

10.  Hypertension with aldosterone excess and low plasma-renin: preoperative distinction between patients with and without adrenocortical tumour.

Authors:  J B Ferriss; J J Brown; R Fraser; A W Kay; A M Neville; I G O'Muircheartaigh; J I Robertson; T Symington; A F Lever
Journal:  Lancet       Date:  1970-11-14       Impact factor: 79.321
View more
  5 in total

Review 1.  Diuretics: mechanism of action and clinical application.

Authors:  D L Davies; G M Wilson
Journal:  Drugs       Date:  1975       Impact factor: 9.546

2.  Spironolactone and risk of upper gastrointestinal events: population based case-control study.

Authors:  Katia Verhamme; Georgio Mosis; Jeanne Dieleman; Bruno Stricker; Miriam Sturkenboom
Journal:  BMJ       Date:  2006-07-13

Review 3.  Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; R Spencer; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study.

Authors:  Sinem E Gulmez; Annmarie T Lassen; Claus Aalykke; Michael Dall; Alin Andries; Birthe S Andersen; Jane M Hansen; Morten Andersen; Jesper Hallas
Journal:  Br J Clin Pharmacol       Date:  2008-04-21       Impact factor: 4.335

5.  Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.

Authors:  Gwen M C Masclee; Huub Straatman; Andrea Arfè; Jordi Castellsague; Edeltraut Garbe; Ron Herings; Bianca Kollhorst; Silvia Lucchi; Susana Perez-Gutthann; Silvana Romio; René Schade; Tania Schink; Martijn J Schuemie; Lorenza Scotti; Cristina Varas-Lorenzo; Vera E Valkhoff; Marco Villa; Miriam C J M Sturkenboom
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.